Clinuvel Pharmaceuticals (CUV.AX)

P/S ratio at the end of 2026: 5.35

According to Clinuvel Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.48. At the end of 2026 the company had a P/S ratio of 5.35.

P/S ratio history for Clinuvel Pharmaceuticals from 2001 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	5.35	-1.4%
2025	5.42	-37.89%
2024	8.73	-22.58%
2023	11.3	1.04%
2022	11.2	-64.69%
2021	31.6	-18.76%
2020	38.9	-25.04%
2019	51.9	151.75%
2018	20.6	3.48%
2017	19.9	-39.14%
2016	32.7	-24.66%
2015	43.5	32.68%
2014	32.8	-19.04%
2013	40.5	-40.37%
2012	67.9	40.48%
2011	48.3
2010	N/A
2009	N/A
2008	N/A	-100%
2007	900	892.81%
2006	90.7	-74.15%
2005	351
2004	N/A
2002	N/A
2001	N/A

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Clinuvel Pharmaceuticals (CUV.AX)